Press release
Progressive Multifocal Leukoencephalopathy Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Inhibikase Therapeutics, Neurimmune, Excision BioTherapeutics,
Progressive Multifocal Leukoencephalopathy Clinical Trials
DelveInsight reports that over three key companies are actively developing more than three therapeutic candidates for Progressive Multifocal Leukoencephalopathy (PML).
Progressive Multifocal Leukoencephalopathy Overview:
Progressive multifocal leukoencephalopathy (PML) is a rare and often life-threatening brain infection. It can occur as a complication of certain medications for multiple sclerosis and other autoimmune disorders, or in individuals with HIV or specific blood and lymphatic cancers. The condition is caused by the John Cunningham (JC) virus, a polyomavirus that remains dormant in the kidneys and bone marrow of more than 60% of adults. PML develops when the virus is reactivated due to prolonged or drug-induced immune suppression, allowing it to invade the brain. This results in irreversible brain damage, severe cognitive and motor impairments, and a high risk of death. Currently, there are no approved therapies for treating PML.
Request for a detailed insights report on Progressive Multifocal Leukoencephalopathy pipeline insights [https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Progressive Multifocal Leukoencephalopathy Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Progressive Multifocal Leukoencephalopathy Therapeutics Market.
Key Takeaways from the Progressive Multifocal Leukoencephalopathy Pipeline Report
*
DelveInsight's Progressive Multifocal Leukoencephalopathy (PML) pipeline report highlights an active landscape with over three companies developing more than three therapeutic candidates for PML.
*
Leading players such as Inhibikase Therapeutics, Neurimmune, Excision BioTherapeutics, I-MAB Biopharma, and others are advancing novel therapies to improve treatment options for PML.
*
Promising candidates in various stages of development include NT-I7, IkT-01427, and others.
*
In October 2022, Cellevolve Bio received FDA clearance for its IND application and Orphan Drug Designation for CE-VST01-JC, an allogeneic, off-the-shelf T cell therapy targeting the JC virus, which causes PML. The company plans to initiate ASCEND-JC, a Phase 2 placebo-controlled trial evaluating the therapy's safety and efficacy, with first patient enrollment expected in the first half of 2023.
*
Earlier, in June 2020, the FDA granted Orphan Drug Designation to NT-I7, a long-acting human interleukin-7 (IL-7), for PML treatment. Subsequently, in February 2021, NeoImmuneTech received FDA clearance for an IND application to begin a pilot study assessing NT-I7's safety and efficacy in PML patients.
Progressive Multifocal Leukoencephalopathy Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Progressive Multifocal Leukoencephalopathy Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Progressive Multifocal Leukoencephalopathy treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Progressive Multifocal Leukoencephalopathy market.
Download our free sample page report on Progressive Multifocal Leukoencephalopathy pipeline insights [https://www.delveinsight.com/sample-request/progressive-multifocal-leukoencephalopathy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Progressive Multifocal Leukoencephalopathy Emerging Drugs
*
NT-I7: NeoImmuneTech
*
IkT-01427: Inhibikase Therapeutics
Progressive Multifocal Leukoencephalopathy Companies
Over three leading companies are engaged in developing therapies for Progressive Multifocal Leukoencephalopathy (PML), with NeoImmuneTech advancing the most progressed candidates, currently in Phase I clinical trials.
DelveInsight's report covers around 3+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Progressive Multifocal Leukoencephalopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Progressive Multifocal Leukoencephalopathy Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Progressive Multifocal Leukoencephalopathy Therapies and Key Companies: Progressive Multifocal Leukoencephalopathy Clinical Trials and advancements [https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Progressive Multifocal Leukoencephalopathy Pipeline Therapeutic Assessment
- Progressive Multifocal Leukoencephalopathy Assessment by Product Type
- Progressive Multifocal Leukoencephalopathy By Stage
- Progressive Multifocal Leukoencephalopathy Assessment by Route of Administration
- Progressive Multifocal Leukoencephalopathy Assessment by Molecule Type
Download Progressive Multifocal Leukoencephalopathy Sample report to know in detail about the Progressive Multifocal Leukoencephalopathy treatment market @ Progressive Multifocal Leukoencephalopathy Therapeutic Assessment [https://www.delveinsight.com/sample-request/progressive-multifocal-leukoencephalopathy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Progressive Multifocal Leukoencephalopathy Current Treatment Patterns
4. Progressive Multifocal Leukoencephalopathy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Progressive Multifocal Leukoencephalopathy Late-Stage Products (Phase-III)
7. Progressive Multifocal Leukoencephalopathy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Progressive Multifocal Leukoencephalopathy Discontinued Products
13. Progressive Multifocal Leukoencephalopathy Product Profiles
14. Progressive Multifocal Leukoencephalopathy Key Companies
15. Progressive Multifocal Leukoencephalopathy Key Products
16. Dormant and Discontinued Products
17. Progressive Multifocal Leukoencephalopathy Unmet Needs
18. Progressive Multifocal Leukoencephalopathy Future Perspectives
19. Progressive Multifocal Leukoencephalopathy Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Progressive Multifocal Leukoencephalopathy Pipeline Reports Offerings [https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=progressive-multifocal-leukoencephalopathy-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-pipeline-inhibikase-therapeutics-neurimmune-excision-biotherapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Progressive Multifocal Leukoencephalopathy Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Inhibikase Therapeutics, Neurimmune, Excision BioTherapeutics, here
News-ID: 4160506 • Views: …
More Releases from ABNewswire
The Difference between Agreement and Agreement stack
Protocol definition is a column of communication annotation, communication of the two sides need to be common in accordance with this standard in computer communication, communication data communication protocol is used to realize the annotation between the computer and network connection, if there is no unified communication protocol, information transmission between the computer cannot be identified, communication protocol is communication rules, can be simply understood as each computer conversation using…
What are the differences between PFAS-free and conventional bagasse food packagi …
Since the 1960s, the U.S. Food and Drug Administration (FDA) has authorized certain PFAS for use in specific food contact applications. Some PFAS are used in cookware, Food Packaging [https://www.foodpackbox.com/food-packaging/], and food processing equipment due to their non-stick properties and resistance to grease, oil, and water. To ensure these substances are safe for their intended use, the FDA conducts a thorough scientific evaluation before authorizing them for market use.
In paper…
Fiber Closure Box: The Key to Ensuring Stable Fiber Transmission
In the chaotic world of online connectivity, efficient and fast stuffy internet connection has ceased to be a luxury but a need in the present-day digitalized world. Fiber optic technology [https://www.oyii.net/news/environmental-benefits-and-sustainable-development-of-optical-fiber-technology/] has become the backbone of modern communication networks, offering unparalleled speed and bandwidth. However, the efficiency of fiber optic networks depends not only on the quality of cables but also on the components that protect and manage them. One…
Nerve Growth Factor Market: Epidemiology, Therapies, Companies, DelveInsight | D …
DelveInsight's "Nerve growth factor (NGF) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Nerve growth factor, historical and forecasted epidemiology as well as the Nerve growth factor market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Nerve Growth Factor therapies are expected to boost the Nerve Growth Factor Market in the upcoming years.
DelveInsight has…
More Releases for Progressive
Progressive Multifocal Leukoencephalopathy Treatment Global Market Report 2024 - …
"The progressive multifocal leukoencephalopathy treatment market size has grown rapidly in recent years. It will grow from $1.31 billion in 2023 to $1.46 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to prevalence of underlying conditions, rise in immunosuppressed patients, patient advocacy and awareness, rise of hiv/aids epidemic.
The progressive multifocal leukoencephalopathy treatment market size is…
Progressive Multifocal Leukoencephalopathy Treatment Market Size 2034
DelveInsight's 'Progressive Multifocal Leukoencephalopathy Market Insights, Epidemiology, and Market Forecast - 2034' report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Progressive Multifocal Leukoencephalopathy in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Key Takeaways from the Progressive Multifocal Leukoencephalopathy Market Report
• According to DelveInsight's analysis, the incident cases of PML in the 7MM were approximately 4…
Benefits of Progressive Web App for A Business
Progressive Web Apps (PWAs) offer numerous benefits for businesses seeking to enhance their online presence and improve user experiences. Firstly, PWAs are designed to work seamlessly across various devices and platforms, including desktops, smartphones, and tablets. This cross-platform compatibility ensures that businesses can reach a wider audience without the need for separate native apps for each operating system, thereby reducing development costs and maintenance efforts.
If you are planning to grow…
Seminar on Progressive Farming
Shri Venkateshwara University/VGI Meerut in collaboration with Bhartiya Kisan Union (Meerut Division) is organizing a 1 day seminar on Progressive farming & farmer the foundation of development on Nov 3rd.In this seminar, the National Organization Minister of All India Farmer's Organization Mr Dinesh Kulkarni, Padamshree Mr Bharat Bhushan Tyagi, & the State Agriculture Minister Mr Baldev Singh Aulakh will take part.Apart from these renowned agriculture scientists, environmentalists, bureaucrats & 400…
Progressive Supranuclear Palsy Headed Toward Cure
Progressive supranuclear palsy (PSP) is a brain disorder which impacts vision, cognition, movement, and speech. This disease results in weakness by affecting certain parts of the brain above the cell clusters, known as nuclei (supranuclear), which are involved in controlling eye movements. It usually manifests in mid-to late adulthood, and the survival rate of people suffering from PSP is five to nine years after the disease first appears. It is…
Progressive Personnel rebrands to Progressive Travel Recruitment
Global travel and hospitality recruitment leader, Progressive Personnel, this month re-emerges as Progressive Travel Recruitment with a fresh new look and a new website under the new URL – www.progressivetravelrecruitment.com – with enhanced job search capability.
Progressive Travel Recruitment’s competitive edge, however, remains – a dedicated team of specialist travel recruiters, who have themselves worked in the industry and understand intimately the needs of travel companies and travel candidates, and…
